Boston Trust Walden Corp Cuts Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Boston Trust Walden Corp lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 866,872 shares of the biopharmaceutical company's stock after selling 7,209 shares during the quarter. Boston Trust Walden Corp owned about 0.70% of Halozyme Therapeutics worth $55,315,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vontobel Holding Ltd. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $377,000. Rhumbline Advisers grew its holdings in shares of Halozyme Therapeutics by 1.4% during the fourth quarter. Rhumbline Advisers now owns 410,508 shares of the biopharmaceutical company's stock valued at $19,626,000 after buying an additional 5,833 shares during the last quarter. State of New Jersey Common Pension Fund D grew its holdings in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock valued at $2,279,000 after buying an additional 302 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $69,000. Finally, Convergence Investment Partners LLC grew its holdings in shares of Halozyme Therapeutics by 25.9% during the fourth quarter. Convergence Investment Partners LLC now owns 34,713 shares of the biopharmaceutical company's stock valued at $1,660,000 after buying an additional 7,151 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now owns 33,108 shares in the company, valued at $2,120,567.40. The trade was a 1.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is owned by insiders.

Analysts Set New Price Targets

HALO has been the topic of a number of research analyst reports. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a research report on Tuesday, May 13th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Finally, Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Stock Performance

HALO opened at $53.15 on Thursday. The stock has a market capitalization of $6.55 billion, a price-to-earnings ratio of 14.14, a PEG ratio of 0.35 and a beta of 1.19. The company has a fifty day moving average of $56.97 and a 200 day moving average of $56.18. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. Halozyme Therapeutics's quarterly revenue was up 35.2% on a year-over-year basis. During the same period last year, the company posted $0.79 earnings per share. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.